Atmo Biosciences has taken a major step toward commercializing its ingestible gas-sensing capsule after RMIT University officially transferred all intellectual property and patents to the company in exchange for equity. The device, initially developed at RMIT, offers real-time insight into gut health by detecting gaseous biomarkers inside the gastrointestinal tract.
Key Highlights:
- Clinical use: The capsule measures gut transit time and regional hydrogen levels to help diagnose disorders like gastroparesis and slow transit constipation, which affect 2 in 5 people.
- Trial success: Over 200 patients in the U.S. and Australia have participated in successful safety and efficacy trials.